Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice

Ruta Dekeryte, Claire Hull, Kaja Plucinska, Shakil Khan, Sarah Kamli-Salino, Nimesh Mody, Nicola Morrice, Chris McLaughlin, Victor Gault, Bettina Platt (Corresponding Author), Mirela Delibegovic (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

We recently reported that brain-specific human β-secretase 1 (BACE1) knock-in (PLB4), a mouse model of ‘sporadic’ Alzheimer’s disease (AD), also develops a severe diabetic phenotype characterised by impaired glucose homeostasis, decreased insulin sensitivity and a fatty liver phenotype. Hence, we here aimed to assess if targeted anti-diabetic therapies (Liraglutide and Fenretinide) would attenuate the diabetic and behavioural phenotype of these mice. PLB4 and wild-type (WT) controls were administered Liraglutide or Fenretinide for ten consecutive weeks alongside vehicle-treated mice. Physiological (body weight and mass composition, glucose tolerance, serum hormone concentration), behavioural (locomotor activity) and molecular assessments were performed in mice pre- and post-treatment. Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice. We also found that PLB4 mice exhibit increased levels of serum dipeptidyl peptidase 4 (DPP4), together with up-regulated hepatic expression of Dpp4, retinol binding protein 4 (Rbp4) and sterol regulatory element-binding 1c (Srebp1c), which was normalised by both treatments. Interestingly, Liraglutide treatment slowed down habituation to a novel environment and increased secondary night activity peak in WT mice, suggesting an impact on circadian activity regulation. However, neither treatment improved glucose homeostasis in PLB4 mice, implying that impaired glucose metabolism in this genotype may not be associated with glucagon like peptide 1 (GLP-1) and/or RBP4-mediated pathways. In summary, this study provides new insights into molecular mechanisms underlying neuronal BACE1-mediated metabolic regulation and implicates BACE1 as a putative regulator of systemic DPP4 levels.
Original languageEnglish
Pages (from-to)222-230
Number of pages9
JournalBiochemical Pharmacology
Volume166
Early online date16 May 2019
DOIs
Publication statusPublished - 1 Aug 2019

Fingerprint

Fenretinide
Phenotype
Dipeptidyl Peptidase 4
Glucose
Retinol-Binding Proteins
Amyloid Precursor Protein Secretases
Glucagon-Like Peptide 1
Sterols
Leptin
Homeostasis
Metabolism
Liver
Serum
Brain
Triglycerides
Liraglutide
Hormones
Insulin
Adiposity
Fatty Liver

Keywords

  • BACE1
  • Type 2 diabetes
  • DPP4
  • Liraglutide
  • Insulin resistance

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. / Dekeryte, Ruta; Hull, Claire; Plucinska, Kaja; Khan, Shakil; Kamli-Salino, Sarah; Mody, Nimesh; Morrice, Nicola; McLaughlin, Chris; Gault, Victor; Platt, Bettina (Corresponding Author); Delibegovic, Mirela (Corresponding Author).

In: Biochemical Pharmacology, Vol. 166, 01.08.2019, p. 222-230.

Research output: Contribution to journalArticle

Dekeryte, Ruta ; Hull, Claire ; Plucinska, Kaja ; Khan, Shakil ; Kamli-Salino, Sarah ; Mody, Nimesh ; Morrice, Nicola ; McLaughlin, Chris ; Gault, Victor ; Platt, Bettina ; Delibegovic, Mirela. / Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. In: Biochemical Pharmacology. 2019 ; Vol. 166. pp. 222-230.
@article{53e9322619274b399d74c965b0affa90,
title = "Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice",
abstract = "We recently reported that brain-specific human β-secretase 1 (BACE1) knock-in (PLB4), a mouse model of ‘sporadic’ Alzheimer’s disease (AD), also develops a severe diabetic phenotype characterised by impaired glucose homeostasis, decreased insulin sensitivity and a fatty liver phenotype. Hence, we here aimed to assess if targeted anti-diabetic therapies (Liraglutide and Fenretinide) would attenuate the diabetic and behavioural phenotype of these mice. PLB4 and wild-type (WT) controls were administered Liraglutide or Fenretinide for ten consecutive weeks alongside vehicle-treated mice. Physiological (body weight and mass composition, glucose tolerance, serum hormone concentration), behavioural (locomotor activity) and molecular assessments were performed in mice pre- and post-treatment. Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice. We also found that PLB4 mice exhibit increased levels of serum dipeptidyl peptidase 4 (DPP4), together with up-regulated hepatic expression of Dpp4, retinol binding protein 4 (Rbp4) and sterol regulatory element-binding 1c (Srebp1c), which was normalised by both treatments. Interestingly, Liraglutide treatment slowed down habituation to a novel environment and increased secondary night activity peak in WT mice, suggesting an impact on circadian activity regulation. However, neither treatment improved glucose homeostasis in PLB4 mice, implying that impaired glucose metabolism in this genotype may not be associated with glucagon like peptide 1 (GLP-1) and/or RBP4-mediated pathways. In summary, this study provides new insights into molecular mechanisms underlying neuronal BACE1-mediated metabolic regulation and implicates BACE1 as a putative regulator of systemic DPP4 levels.",
keywords = "BACE1, Type 2 diabetes, DPP4, Liraglutide, Insulin resistance",
author = "Ruta Dekeryte and Claire Hull and Kaja Plucinska and Shakil Khan and Sarah Kamli-Salino and Nimesh Mody and Nicola Morrice and Chris McLaughlin and Victor Gault and Bettina Platt and Mirela Delibegovic",
note = "The authors would like to acknowledge University of Aberdeen PhD studentship to RD and Scottish Alzheimer’s Research UK Junior member research grant to RD to perform GLP-1 ELISA and Alzheimer’s Research UK grant to BP and MD (ARUK-PG2017B-11). We thank Dr Oliver Helk for advice concerning statistical analyses and Prof Gernot Riedel for kindly providing the PhenoTyper home cages and advice in behavioural studies.",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.bcp.2019.05.020",
language = "English",
volume = "166",
pages = "222--230",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice

AU - Dekeryte, Ruta

AU - Hull, Claire

AU - Plucinska, Kaja

AU - Khan, Shakil

AU - Kamli-Salino, Sarah

AU - Mody, Nimesh

AU - Morrice, Nicola

AU - McLaughlin, Chris

AU - Gault, Victor

AU - Platt, Bettina

AU - Delibegovic, Mirela

N1 - The authors would like to acknowledge University of Aberdeen PhD studentship to RD and Scottish Alzheimer’s Research UK Junior member research grant to RD to perform GLP-1 ELISA and Alzheimer’s Research UK grant to BP and MD (ARUK-PG2017B-11). We thank Dr Oliver Helk for advice concerning statistical analyses and Prof Gernot Riedel for kindly providing the PhenoTyper home cages and advice in behavioural studies.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - We recently reported that brain-specific human β-secretase 1 (BACE1) knock-in (PLB4), a mouse model of ‘sporadic’ Alzheimer’s disease (AD), also develops a severe diabetic phenotype characterised by impaired glucose homeostasis, decreased insulin sensitivity and a fatty liver phenotype. Hence, we here aimed to assess if targeted anti-diabetic therapies (Liraglutide and Fenretinide) would attenuate the diabetic and behavioural phenotype of these mice. PLB4 and wild-type (WT) controls were administered Liraglutide or Fenretinide for ten consecutive weeks alongside vehicle-treated mice. Physiological (body weight and mass composition, glucose tolerance, serum hormone concentration), behavioural (locomotor activity) and molecular assessments were performed in mice pre- and post-treatment. Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice. We also found that PLB4 mice exhibit increased levels of serum dipeptidyl peptidase 4 (DPP4), together with up-regulated hepatic expression of Dpp4, retinol binding protein 4 (Rbp4) and sterol regulatory element-binding 1c (Srebp1c), which was normalised by both treatments. Interestingly, Liraglutide treatment slowed down habituation to a novel environment and increased secondary night activity peak in WT mice, suggesting an impact on circadian activity regulation. However, neither treatment improved glucose homeostasis in PLB4 mice, implying that impaired glucose metabolism in this genotype may not be associated with glucagon like peptide 1 (GLP-1) and/or RBP4-mediated pathways. In summary, this study provides new insights into molecular mechanisms underlying neuronal BACE1-mediated metabolic regulation and implicates BACE1 as a putative regulator of systemic DPP4 levels.

AB - We recently reported that brain-specific human β-secretase 1 (BACE1) knock-in (PLB4), a mouse model of ‘sporadic’ Alzheimer’s disease (AD), also develops a severe diabetic phenotype characterised by impaired glucose homeostasis, decreased insulin sensitivity and a fatty liver phenotype. Hence, we here aimed to assess if targeted anti-diabetic therapies (Liraglutide and Fenretinide) would attenuate the diabetic and behavioural phenotype of these mice. PLB4 and wild-type (WT) controls were administered Liraglutide or Fenretinide for ten consecutive weeks alongside vehicle-treated mice. Physiological (body weight and mass composition, glucose tolerance, serum hormone concentration), behavioural (locomotor activity) and molecular assessments were performed in mice pre- and post-treatment. Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice. We also found that PLB4 mice exhibit increased levels of serum dipeptidyl peptidase 4 (DPP4), together with up-regulated hepatic expression of Dpp4, retinol binding protein 4 (Rbp4) and sterol regulatory element-binding 1c (Srebp1c), which was normalised by both treatments. Interestingly, Liraglutide treatment slowed down habituation to a novel environment and increased secondary night activity peak in WT mice, suggesting an impact on circadian activity regulation. However, neither treatment improved glucose homeostasis in PLB4 mice, implying that impaired glucose metabolism in this genotype may not be associated with glucagon like peptide 1 (GLP-1) and/or RBP4-mediated pathways. In summary, this study provides new insights into molecular mechanisms underlying neuronal BACE1-mediated metabolic regulation and implicates BACE1 as a putative regulator of systemic DPP4 levels.

KW - BACE1

KW - Type 2 diabetes

KW - DPP4

KW - Liraglutide

KW - Insulin resistance

UR - https://linkinghub.elsevier.com/retrieve/pii/S0006295219301959

UR - http://www.mendeley.com/research/effects-liraglutide-fenretinide-treatments-diabetic-phenotype-neuronal-human-bace1-knockin-mice

UR - http://www.scopus.com/inward/record.url?scp=85066461300&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2019.05.020

DO - 10.1016/j.bcp.2019.05.020

M3 - Article

VL - 166

SP - 222

EP - 230

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -